Abstract | CONTEXT: OBJECTIVE: DESIGN, SETTING, AND PARTICIPANTS: Population-based observational study of cases of invasive serogroup C meningococcal disease from 1996 through 2002 in Quebec identified from the provincial registry of notifiable diseases and from the provincial reference laboratory. In 2001, a mass immunization campaign with a conjugate vaccine was conducted to control an emerging epidemic. The number of vaccinated individuals was extracted from meningococcal immunization registries. MAIN OUTCOME MEASURES: Incidence of invasive meningococcal disease before and 1 year after the campaign in vaccinated and unvaccinated individuals. RESULTS: Vaccination coverage of those 2 months to 20 years was 82.1%. After the campaign, the number of cases of serogroup C disease decreased from 58 in 2001 to 27 in 2002, and the incidence from 7.8 per million to 3.6 per million. Vaccine effectiveness was found to be 96.8% (95% confidence interval, 75.0%-99.9%). There was no observed increase in the incidence of the other serogroups. CONCLUSION:
|
Authors | Philippe De Wals, Geneviève Deceuninck, Nicole Boulianne, Gaston De Serres |
Journal | JAMA
(JAMA)
Vol. 292
Issue 20
Pg. 2491-4
(Nov 24 2004)
ISSN: 1538-3598 [Electronic] United States |
PMID | 15562128
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Meningococcal Vaccines
- serogroup C meningococcal conjugate vaccine
|
Topics |
- Adolescent
- Adult
- Child
- Child, Preschool
- Humans
- Incidence
- Infant
- Mass Vaccination
- Meningococcal Infections
(epidemiology, prevention & control)
- Meningococcal Vaccines
(administration & dosage)
- Neisseria meningitidis, Serogroup C
- Quebec
(epidemiology)
|